KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Capital Expenditures: 2010-2024

Historic Capital Expenditures for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $725,000.

  • Supernus Pharmaceuticals' Capital Expenditures fell 35.50% to $129,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 136.13%. This contributed to the annual value of $725,000 for FY2024, which is 31.58% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Capital Expenditures is $725,000, which was up 31.58% from $551,000 recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Capital Expenditures ranged from a high of $3.4 million in FY2020 and a low of $412,000 during FY2022.
  • Its 3-year average for Capital Expenditures is $562,667, with a median of $551,000 in 2023.
  • Data for Supernus Pharmaceuticals' Capital Expenditures shows a peak YoY soared of 33.74% (in 2023) over the last 5 years.
  • Supernus Pharmaceuticals' Capital Expenditures (Yearly) stood at $3.4 million in 2020, then reached $412,000 in 2022, then soared by 33.74% to $551,000 in 2023, then skyrocketed by 31.58% to $725,000 in 2024.